EU approves new dosing schedule for MSD’s Keytruda by Anna Smith | Apr 5, 2019 | News | 0 The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals. Read More
BMS’ Opdivo cleared for monthly use by Selina McKee | Mar 7, 2018 | News | 0 US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. Read More